| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 57.3MM | +2% |
| Gross Profit | 23.3MM | -4% |
| Cost Of Revenue | 34MM | +7% |
| Operating Income | -69.9MM | - |
| Operating Expenses | 93.1MM | - |
| Net Income | -62.4MM | - |
| R&D | 4.7MM | -8% |
| G&A | 38.8MM | +8% |
| Amortization | 4.6MM | +15% |
| Interest Expense | 1.3MM | -4% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
There's been a notable change in appetite for Cryoport, Inc. ( NASDAQ:CYRX ) shares in the week since its yearly...
Cryoport ( NASDAQ:CYRX ) Full Year 2023 Results Key Financial Results Revenue: US$233.3m (down 1.7% from FY 2022). Net...
Cryoport, Inc. (NASDAQ:CYRX) Q4 2023 Earnings Call Transcript March 12, 2024 Cryoport, Inc. misses on earnings expectations. Reported EPS is $-1.31 EPS, expectations were $-0.32. Cryoport, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to […]
Revenue Guidance Set for Progressive Growth in 2024
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -59.38% and 1.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023. Jerrell Shelton, CEO of Cryoport, commented, "Today we reported full year results including total revenue of $233.3 million for the fiscal year ended December 31, 2023. Our results were within our revenue guidance range, despite the challenging operating environment we experienced thro
Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is it a good or bad thing when a stock experiences a golden cross technical event?
It is doubtless a positive to see that the Cryoport, Inc. ( NASDAQ:CYRX ) share price has gained some 50% in the last...